Video

Dr. Heymach on New KRAS Subsets in Lung Cancer

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

Heymach says that KRAS-mutant lung cancer and treatment for it is the number one problem in this specific field. In this study, researchers examined KRAS with techniques such as DNA sequencing, mRNA sequencing, immune profiling and proteomics.

It was discovered that KRAS can be broken down into three major subgroups. These groups are believed to be caused by additional mutations, such as P53.

Because of these identified subgroups, Heymach says researchers can now see how they each respond to treatments. In the past, targeted therapies for KRAS mutations were not often effective, but Heymach adds this may change through focusing on a specific subgroup versus KRAS as a whole.

<<<

View more from the 2015 AACR Annual Meeting

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Noman Ashraf, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.